CRIPTO and cancer: Other interesting approaches include targeting membrane molecules with a role in BCSC function, the so called “oncoantigens” (92): among others, CD44, xCT, Chondroitin Sulfate Proteoglycan 4 and Cripto1 (58, 61, 71, 93) that, when inhibited, would compromise the stem-like properties of cancer cells, making them sensitive to standard therapies.